Aptamers against interleukin-12-related cytokines as novel therapeutics in autoimmune diseases

Bibliography

• KEANE J, GERSHON S, WISE RP et al.: Tuberculosis associated with infliximab, a tumour necrosis factor α-neutralizing agent. N. Engl. J. Med. (2001) 345:1098-1104.
   PubMed Web of Science ®Google Scholar
• EHLERS S, HÖLSCHER C: DTH-associated pathology. In: Topley and Wilson’s Microbiology and Microbial Infections. S Kaufmann (Ed.), Arnold Publishing, London, UK (2005):705-730.
   Google Scholar
• GLIMCHER LH, MURPHY KM: Lineage commitment in the immune system: the T helper lymphocyte grows up. Genes Dev. (2000) 14:1693-1711.
   PubMed Web of Science ®Google Scholar
• HÖLSCHER C: The power of combinatorial immunology: IL-12 and IL-12-related dimeric cytokines in infectious diseases. Med. Microbiol. Immunol (Berl) (2004) 193:1-17.
   PubMed Web of Science ®Google Scholar
• CASPI RR: IL-12 in autoimmunity. Clin. Immunol. Immunopathol. (1998) 88:4-13.
   PubMedGoogle Scholar
• OPPMANN B, LESLEY R, BLOM B et al.: Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity (2000) 13:715-725.
   PubMed Web of Science ®Google Scholar
• PARHAM C, CHIRICA M, TIMANS J et al.: A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. (2002) 168:5699-5708.
   PubMed Web of Science ®Google Scholar
• MURPHY CA, LANGRISH CL, CHEN Y et al.: Divergent pro- and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. (2003) 198:1951-1957.
   PubMed Web of Science ®Google Scholar
• LANGRISH CL, CHEN Y, BLUMENSCHEIN WM et al.: IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. (2005) 201:233-240.
   PubMed Web of Science ®Google Scholar
• CUA DJ, SHERLOCK J, CHEN Y et al.: Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature (2003) 421:744-748.
   PubMed Web of Science ®Google Scholar
• PARK H, LI Z, YANG XO et al.: A distinct lineage of CD4 T cells regulates tissue inflammation by producing IL-17. Nat. Immunol. (2005) 6:1133-1141.
   PubMed Web of Science ®Google Scholar
• HARRINGTON LE, HATTON RD, MANGAN PR et al.: IL-17-producing CD4 effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. (2005) 6:1123-1132.
   PubMed Web of Science ®Google Scholar
• NAKAE S, NAMBU A, SUDO K, IWAKURA Y: Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J. Immunol. (2003) 171:6173-6177.
   PubMed Web of Science ®Google Scholar
• LAUWERYS BR, VAN SJ, HOUSSIAU FA: Serum IL-12 in systemic lupus erythematosus: absence of p70 heterodimers but presence of p40 monomers correlating with disease activity. Lupus (2002) 11:384-387.
   PubMed Web of Science ®Google Scholar
• LEE E, TREPICCHIO WL, OESTREICHER JL et al.: Increased expression of IL-23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. (2004) 199:125-130.
   PubMed Web of Science ®Google Scholar
• NEURATH MF, FUSS I, KELSALL BL, STUBER E, STROBER W: Antibodies to IL-12 abrogate established experimental colitis in mice. J. Exp. Med. (1995) 182:1281-1290.
   PubMed Web of Science ®Google Scholar
• LO CH, LEE SC, WU PY et al: Antitumour and antimetastatic activity of IL-23. J. Immunol. (2003) 171:600-607.
   PubMed Web of Science ®Google Scholar
• WANG YQ, UGAI S, SHIMOZATO O et al.: Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells. Int. J. Cancer (2003) 105:820-824.
   PubMed Web of Science ®Google Scholar
• HÖLSCHER C: Targeting IL-23 in autoimmunity. Curr. Opin. Investig. Drugs (2005) 6:489-495.
   PubMedGoogle Scholar
• FAMULOK M, MAYER G: Aptamers as tools in molecular biology and immunology. Curr. Top. Microbiol. Immunol. (1999) 243:123-136.
   PubMed Web of Science ®Google Scholar
• TOMBELLI S, MINUNNI M, MASCINI M: Analytical applications of aptamers. Biosens. Bioelectron. (2005) 20:2424-2434.
   PubMed Web of Science ®Google Scholar
• VANDENBROECK K, ALLOZA I, GADINA M, MATTHYS P: Inhibiting cytokines of the interleukin-12 family: recent advances and novel challenges. J. Pharm. Pharmacol. (2004) 56:145-160.
   PubMed Web of Science ®Google Scholar
• UYTTENHOVE C, ARENDSE B, STROOBANT V, BROMBACHER F, VAN SNICK J: Development of an anti-IL-12 p40 auto-vaccine: protection in experimental autoimmune encephalomyelitis at the expense of increased sensitivity to infection. Eur. J. Immunol. (2004) 34:3572-3581.
   PubMed Web of Science ®Google Scholar
• HÖLSCHER C, KÖHLER G, MÜLLER U, MOSSMANN H, SCHAUB GA, BROMBACHER F: Defective nitric oxide effector functions lead to extreme susceptibility of Trypanosoma cruzi-infected mice deficient in gamma interferon receptor or inducible nitric oxide synthase. Infect. Immun. (1998) 66:1208-1215.
   PubMed Web of Science ®Google Scholar
• MÜLLER U, KÖHLER G, MOSSMANN H et al.: IL-12-independent IFN-γ production by T cells in experimental Chagas’ disease is mediated by IL-18. J. Immunol. (2001) 167:3346-3353.
   PubMed Web of Science ®Google Scholar
• LIEBERMAN LA, CARDILLO F, OWYANG AM et al.: IL-23 provides a limited mechanism of resistance to acute toxoplasmosis in the absence of IL-12. J. Immunol. (2004) 173:1887-1893.
   PubMed Web of Science ®Google Scholar